David Tse, M.D., FACS, Professor of Ophthalmology and the Dr. Bascom Palmer is virtually unmatched as a world leader in vision research and care and their interest in MYMD-1 validates our belief in the potential of the drug for autoimmune and inflammatory conditions.”ĭr. The reported incidence of TON ranges from 1.5% to 4% following head trauma 1, and each year an estimated 2.8 million Americans sustain a traumatic brain injury 2.Ĭhris Chapman, M.D., President, Director and Chief Medical Officer of MyMD, commented, “We are excited about this agreement with our country’s top eye institute to test our lead drug candidate MYMD-1 in ophthalmology. Visual impairment is usually caused by blunt force trauma to the head. TON is a condition caused by injury to the optic nerve, resulting in partial or complete vision loss. The project is fully funded by Bascom Palmer Eye Institute.
® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that it has entered into a material transfer agreement (MTA) with Bascom Palmer Eye Institute of Miami, Florida to collaborate on a pre-clinical study using MYMD-1 ® as a potential treatment for traumatic optic neuropathy (TON).
BALTIMORE-( BUSINESS WIRE)- MyMD Pharmaceuticals, Inc.
0 kommentar(er)
